share_log

6-K: Novo Nordisk A/S – Reduction of the Share Capital

6-K: Novo Nordisk A/S – Reduction of the Share Capital

諾和諾德 | 6-K：諾和諾德 - 股本削減
美股sec公告 ·  04/25 06:05
Moomoo AI 已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has successfully completed the reduction of its B share capital as announced at its Annual General Meeting on March 21, 2024. The reduction involved the cancellation of 45,000,000 B shares, resulting in a decrease of the B share capital from DKK 343,512,800 to DKK 339,012,800. Following the reduction, the total share capital of Novo Nordisk stands at DKK 446,500,000, split into A and B shares. The company confirmed that this capital adjustment will not impact its ongoing share repurchase program. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.
Novo Nordisk A/S, a leading global healthcare company, has successfully completed the reduction of its B share capital as announced at its Annual General Meeting on March 21, 2024. The reduction involved the cancellation of 45,000,000 B shares, resulting in a decrease of the B share capital from DKK 343,512,800 to DKK 339,012,800. Following the reduction, the total share capital of Novo Nordisk stands at DKK 446,500,000, split into A and B shares. The company confirmed that this capital adjustment will not impact its ongoing share repurchase program. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.
全球領先的醫療保健公司諾和諾德A/S已成功完成其在2024年3月21日的年度股東大會上宣佈的B股本削減。削減涉及取消45,000,000股B股，導致B股本從343,512,800丹麥克朗減少至339,012,800丹麥克朗。減持後，諾和諾德的總股本爲44.65萬丹麥克朗，分爲A股和B股。該公司證實，此次資本調整不會影響其正在進行的股票回購計劃。諾和諾德的歷史可以追溯到1923年，致力於抗擊嚴重的慢性病，在80個國家擁有約63,400名員工。該公司的B股在哥本哈根納斯達克上市，其ADR在紐約證券交易所上市，股票代碼爲NVO。
全球領先的醫療保健公司諾和諾德A/S已成功完成其在2024年3月21日的年度股東大會上宣佈的B股本削減。削減涉及取消45,000,000股B股，導致B股本從343,512,800丹麥克朗減少至339,012,800丹麥克朗。減持後，諾和諾德的總股本爲44.65萬丹麥克朗，分爲A股和B股。該公司證實，此次資本調整不會影響其正在進行的股票回購計劃。諾和諾德的歷史可以追溯到1923年，致力於抗擊嚴重的慢性病，在80個國家擁有約63,400名員工。該公司的B股在哥本哈根納斯達克上市，其ADR在紐約證券交易所上市，股票代碼爲NVO。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息